[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-wasting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-wasting":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,65,99,132,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100643710","effects-of-dietary-supplementation-with-omega3-fatty-acids-fish-oil-and-progressive-resistance-training-on-skeletal-muscle-status-in-gynaecological-gastrointestinal-and-urological-cancer-patients-100643710",false,"NCT07643558","Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients","SUPPORT-Study = Effects of a Dietary SUPPlementation With Omega3-fatty Acids\u002F Fish Oil and Progressive Resistence Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal, and Urological Cancer Patients","SUPPORT","Inclusion Criteria:\n\n* Patients with malignant tumors undergoing curative or palliative treatment, including breast, ovarian, esophageal, pancreatic, gastric, colon, rectal, and prostate cancer, across all UICC stages\n* Women and men aged 18 years or older\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Bone metastases or skeletal involvement associated with a high risk of fracture\n* Pregnant or breastfeeding women\n* Patients with psychiatric disorders that raise concerns regarding decision-making capacity or ability to provide informed consent\n* Participation in other exercise and\u002For nutritional intervention studies within the previous 3 months\n* Current use of fish oil supplements\n* Severe cardiovascular disease, NYHA class IV","ALL","18 Years",{"count":20,"type":21},288,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of skeletal muscle mass, physical performance, and quality of life. Muscle wasting negatively affects the tolerability and efficacy of oncological therapies and exacerbates distressing symptoms such as fatigue. Consequently, international guidelines recommend combined nutritional and exercise interventions as key components of supportive cancer care. However, due to treatment-related limitations, conventional exercise programs are often difficult to implement, highlighting the need for feasible, time-efficient, and individually adaptable training concepts suitable for daily life.\n\nIn addition, adequate protein-rich nutrition is essential and may be supported by targeted nutritional supplementation. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have demonstrated anti-inflammatory effects and beneficial influences on nutritional status, quality of life, and potentially skeletal muscle mass.\n\nThe aim of the present project is to investigate, in a randomized, placebo-controlled trial, whether the combination of progressive resistance training (twice-weekly TheraBand-based exercise) and omega-3 supplementation (daily intake of 2 g EPA and 1 g DHA administered as fish oil capsules) can improve muscle status, physical performance, and patient-relevant outcomes such as quality of life, appetite, and fatigue in cancer patients at high risk of developing cancer cachexia.",[27,28,29,30,31,32],"Cancer Cachexia","Omega 3","Resistance Training","Cancer","Muscle Wasting","Systemic Inflammation",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"Resistance training","Progressive resistance exercise","Exercise therapy","Supportive cancer care","Nutritional intervention","Protein-rich nutrition","Nutritional supplementation","Omega-3 fatty acids","Eicosapentaenoic acid (EPA)","Docosahexaenoic acid (DHA)","Fish oil supplementation","Physical performance","Quality of life","Fatigue","Appetite","Patient-reported outcomes","Randomized placebo-controlled trial","Cachexia risk","RECRUITING","2026-06-08",{"date":55,"type":56},"2026-06-11","ACTUAL",{"date":58,"type":56},"2026-01-01",{"date":60,"type":21},"2029-10",{"name":62,"class":63},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":64},"100638447","muscle-ultrasound-for-sarcopenia-assessment-in-kidney-transplant-recipients-100638447","NCT07607236","Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients","A Prospective Observational Study of Multimodal Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients","KT-SARC","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients scheduled to undergo kidney transplantation\n* Ability to undergo muscle ultrasound and bioelectrical impedance analysis (BIA)\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with severe limb deformity or conditions preventing muscle ultrasound assessment\n* Patients with implanted electronic devices contraindicating BIA assessment\n* Inability to complete study assessments","80 Years",{"count":75,"type":21},140,"OBSERVATIONAL","This is a single-center prospective observational study designed to evaluate the effectiveness of multimodal muscle ultrasound for the assessment of sarcopenia in kidney transplant recipients. Adult patients undergoing kidney transplantation will undergo both muscle ultrasound and bioelectrical impedance analysis (BIA) at predefined time points before and after transplantation.\n\nThe primary objective is to evaluate the diagnostic performance of muscle ultrasound for sarcopenia assessment, including its correlation and agreement with BIA-derived skeletal muscle index (BIA-SMI), as well as its diagnostic accuracy. Secondary objectives include describing the longitudinal changes in sarcopenia prevalence and muscle-related parameters from the pre-transplant period to 1 year after transplantation.\n\nThe study aims to provide evidence for a convenient, noninvasive, radiation-free, and reliable method for sarcopenia assessment in kidney transplant recipients.",[79,80,31],"Sarcopenia","Kidney Transplantation",[82,83,84,85,86,87,88],"Muscle Ultrasound","Bioelectrical Impedance Analysis","BIA-SMI","Kidney Transplant Recipient","Muscle Mass","Frailty","Prospective Cohort","NOT_YET_RECRUITING","2026-05-19",{"date":92,"type":56},"2026-05-26",{"date":94,"type":21},"2026-05-30",{"date":96,"type":21},"2028-01-30",{"name":98,"class":63},"Sichuan Provincial People's Hospital",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100624572","phase-2-testing-the-efficacy-safety-and-pk-of-20e-in-patients-with-obesity-who-are-starting-treatment-with-the-glp-1-agonist-semaglutide-for-weight-loss-100624572","NCT07411378","Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of 20-hydroxyecdysone (20E) in Reducing the Muscle Strength Loss From the GLP1 Agonist Semaglutide in Combination With Dieting in Obese and Overweight Adult Patients (OBA).","OBA","Inclusion Criteria:\n\n* Willing to participate and able to sign an ICF\n* BMI ≥30 or BMI ≥27 with one or more weight-associated co-morbidities (e.g. hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease)\n* Start of treatment with semaglutide for weight loss at Day 3 after the start of the study treatment\n* Willing to maintain a diet with an average intake of at least 1 gr\u002Fkg body weight protein daily\n* Willing to maintain sufficient exercise, i.e. at least 150 minutes per week moderate-vigorous exercise\n* Body weight stable (within a 5 kg range) in the 3 months prior to enrolment\n* Female participants should be at least 12 months post-menopausal) or surgically sterile OR have a negative urine pregnancy test at screening and be willing to use a contraceptive method from screening to 90 days after last dose.\n* Based on Semaglutide long half-life, participants should consent to use a contraception method 3 months after administration of the last dose intake of semaglutide.\n\nExclusion Criteria:\n\n* Participant not able to take medications by mouth (as capsules)\n* Use of disallowed concomitant medications or herbal products: Any herbal products containing 20-hydroxyecdysone and derived from Leuzea carthamoides, Cyanotis vaga, or Cyanotis arachnoidea are not allowed and any other anabolic products, GH\u002FIGF-1 products, spironolactone, metformin, chemotherapeutic agents, antidepressants, and systemic glucocorticoids within three months prior to study enrollment or strong inhibitors of the Organic Anion Transporting Polypeptide (OATP1B3) e.g. rifampicin and cyclosporine. Use of muscle strength-supporting food supplements\n* Any known hypersensitivity to any of the active substances (20E), and its excipients (the study medication) and the active substance and the excipients of semaglutide.\n* History or present cholelithiasis or cholecystectomy from medical history or sludge or stones observed on gallbladder ultrasound or any other method.\n* Presence of contra-indications to semaglutide per current semaglutide Prescribing Information \u002F Summary of Product Characteristics\n* Current diabetes (both insulin dependent and T2DM)\n* A history of chronic pancreatitis or acute pancreatitis\n* Previous surgical obesity treatment or planned obesity surgery during the study period\n* Use of anti-obesity (weight-loss) medication or use of any GLP-1 RA for diabetes within 90 days before enrollment\n* BMI \\>40\n* Uncontrolled hypertension (RR above 150\u002F100 mmHg)\n* NYHA Class III or IV CHF\n* History of stroke, myocardial infarction, life-threatening arrhythmia, or coronary revascularization within 6 months prior to screening\n* Clinically significant liver disease, ALT\u002FAST \\>5x ULN, or total bilirubin \\> 2x ULN, unless the patient has known Gilbert's syndrome\n* Neuromuscular disorder or CK \\>5x ULN\n* Autoimmune\u002Finflammatory disorders that may cause muscle wasting\n* Use of antipsychotics, amphetamines, or any other treatments that can affect weight\n* Clinically significant ECG abnormalities\n* History of major depressive disorder within the last 2 years\n* Any lifetime history of suicide attempt\n* History of any suicidal behavior in the last month\n* History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder\n* Baseline PHQ-9 score ≥15 or any suicidal ideation of level 4 or level 5 on the Columbia-Suicide Severity Rating Scale\n* History or current gastroparesis (from medical history)\n* Patients with obesity due to other endocrinologic disorders\n* eGFR ≤60 mL\u002Fmin\u002F1.73 m2, based on Cockcroft \\& Gault formula OR Participant requiring renal dialysis\n* Patients with clinically Recognized Eating Disorders\n* Patients with clinically significant, uncontrolled hyperthyroidism or hypothyroidism, or those with newly diagnosed thyroid disease within the past 3 months.","84 Years",{"count":109,"type":21},164,[111],"PHASE2","The goal of this clinical trial is to learn if BIO101 treatment can improve the muscle strength of participants males and females, aged 18 to 84 years old, suffering from obesity (BMI≥30) or overweight (BMI ≥ 27) with one or more sequelae (e.g., hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, but excluding diabetes), and treated with semaglutide, a GLP1 agonist for 21 weeks. The main questions it aims to answer are:\n\n* Is BIO101 administered orally improving muscle strength, as measured with knee extension strength (using isokinetic dynamometry)?\n* Is BIO101 administration leading to additional medical problems for patients suffering from obesity or overweight with sequelae and treated with semaglutide? After the end of the study (after last patient did the last visit at the clinic), researchers will compare the BIO101-treated arm to the placebo control arm to see if the candidate drug has an effect on muscle strength, physical function, lean body mass and health related quality of life compared to placebo. BIO101 is the candidate drug and placebo is a look-alike substance that does not contain any active drug\n\nParticipants will be asked to:\n\n* Take 2 pills every morning and every evening of BIO101 or placebo orally for 21 weeks.\n* Simultaneously, take semaglutide for 21 weeks while being on caloric restriction, following the doctor recommendation and approved prescribing information for semaglutide, with dose increasing up to at least a dose level of 1.7 mg and a maximum dose level of 2.4 mg.\n* Come to investigational site at screening, baseline, week 6, 13, 21 and week 33 (12 weeks after the end of treatment) for checkups and tests.\n* Answer to phone calls at week 25 and 29 as well (4 and 8 weeks after the end of treatment) on global health status and quality of life.",[31,114,115],"Obesity & Overweight","Obesity",[117,118,119,120,121],"obesity","overweight","muscle","strength","physical performance","2026-02-11",{"date":124,"type":56},"2026-02-13",{"date":126,"type":21},"2026-07",{"date":128,"type":21},"2027-08",{"name":130,"class":131},"Biophytis","INDUSTRY",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":64},"100597751","the-effect-of-repeated-whole-body-nmes-sessions-with-or-without-protein-intake-on-muscle-protein-synthesis-during-3-days-of-bed-rest-in-healthy-young-volunteers-100597751","NCT07062562","The Effect of Repeated Whole-body NMES Sessions With or Without Protein Intake on Muscle Protein Synthesis During 3 Days of Bed Rest in Healthy Young Volunteers","The Effect of Repeated Sessions of Whole-body Neuromuscular Electrical Stimulation (NMES), With or Without Subsequent Intake of a Protein Bolus, on Muscle Protein Synthesis in Healthy, Young Volunteers During 3 Days of Bed Rest","SPRINT","Inclusion Criteria:\n\n* Aged from 18-35 years\n* 18.5 \\\u003C BMI \\\u003C 30 kg·m2\n* Recreationally active (performing non-competitive physical exercise at least one time per week for minimally 30 minutes)\n\nExclusion Criteria:\n\n* Employed or undertaking a thesis or internship at the department of Human and Animal Physiology at Wageningen University\n* Smoking\n* Diabetes (Type 1, Type 2, or genetic form of diabetes)\n* Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and\u002For\n\n  ≥90 mmHg diastolic)\n* Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices)\n* Known allergy to lidocaine\n* Prone to keloid forming (i.e. hyperplastic growth of scars)\n* All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g.\n\narthritis, spasticity\u002Frigidity, all neurological disorders and paralysis)\n\n* Regular use of dietary protein and\u002For amino acid supplements (\\>3 times per week)\n* Currently involved in a structured progressive resistance training programme (\\>3 times per week)\n* A personal or family history of thrombosis (clots), epilepsy, seizures, or schizophrenia\n* Any previous motor disorders or disorders in muscle and\u002For lipid metabolism\n* Any back, leg, knee, neck, shoulder or postural complaints\n* Presence of an ulcer in the stomach or gut and\u002For strong history of indigestion\n* Contra-indications for DXA scans (e.g. undergoing radiologic examination)\n* Lactose intolerance\n* Known severe kidney problems\n* Pregnant or breastfeeding\n* Unable to give consent",true,"35 Years",{"count":143,"type":21},42,[24],"The goal of this clinical trial is to examine the effect of whole-body electrostimulation with protein intake on muscle protein synthesis, muscle mass and function during bed rest in healthy young adults (18-35 years). The main questions to answer are:\n\n* Does whole-body NMES followed by protein intake improve muscle protein synthesis rates during 3 days of bed rest?\n* Does repeated NMES sessions offer protective effects on muscle mass and function during extended periods of inactivity?\n\nResearchers will compare sham electrical electrostimulation, electrical stimulation and electrical stimulation + protein groups to see if whole-body electrostimulation combined with protein intake offers the greatest improvement in muscle protein metabolism and muscle preservation.\n\nParticipants will:\n\n* Undergo 3 days of bed rest while receiving one of the following interventions:\n\n  * Sham-NMES followed by standard nutrition (CON)\n  * Whole-body NMES followed by standard nutrition(NMES)\n  * Whole-body NMES followed by a bolus of 20g protein (NMES+PRO)\n* Receive heavy water (D2O) to assess body water turnover.\n* Undergo leg extension exercises to assess muscle function.\n* Have quadriceps muscle thickness measured via ultrasound.\n* Provide saliva samples for analysis.\n* Have calf circumference measured to monitor changes in muscle mass.",[31],[148,149,150,151],"NMES","Skeletal Muscle Metabolism","Protein","Disuse","2025-07-09",{"date":154,"type":56},"2025-07-14",{"date":156,"type":56},"2025-05-22",{"date":158,"type":21},"2027-05",{"name":160,"class":63},"Wageningen University",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":76,"phases":4,"briefSummary":171,"conditions":172,"keywords":178,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100569686","muscle-and-subcutaneous-tissue-variation-by-ultrasound-and-impedance-linked-to-fluid-balance-in-icu-patients-100569686","NCT06697470","Muscle and Subcutaneous Tissue Variation by Ultrasound and Impedance Linked to Fluid Balance in ICU Patients","Cross-sectional Study on the Variation of Muscle Thickness and Subcutaneous Tissues by Ultrasound and Bioelectrical Impedance in Association with the Fluid Balance of Patients in Intensive Care","Inclusion Criteria:\n\n* Adults aged over 18 years.\n* Patients present and admitted to the ICU at Epicura Hornu Hospital between October 14, 2024, and November 15, 2024 (to be updated).\n* Informed consent to participate in the study has been signed by the patient or their legal representative.\n\nExclusion Criteria :\n\n* Patients in post-operative or other surveillance with an expected ICU stay of less than 48 hours.\n* Patients for whom a decision to withdraw therapy has been made prior to inclusion.\n* Presence of skin conditions (e.g., wounds or ulcers) that hinder ultrasound measurements or the application of skin electrodes.\n* Pregnancy.\n* Presence of an implanted pacemaker or defibrillator.",{"count":169,"type":21},40,"5 Days","This cross-sectional study aims to investigate the relationship between variations in muscle thickness and subcutaneous tissue, measured by ultrasound, and fluid compartments, evaluated using bioelectrical impedance analysis (BIA), in critically ill patients in the intensive care unit (ICU). Critically ill patients frequently experience muscle wasting and tissue edema due to a combination of inflammation, immobilization, and aggressive fluid resuscitation protocols designed to counteract hemodynamic instability.\n\nUltrasound is widely used to monitor muscle thickness because it is fast, non-invasive, and repeatable. However, muscle thickness measurements during the first days of ICU admission may be influenced by fluid overload, which causes edema and might lead to an overestimation of actual muscle mass. Bioelectrical impedance analysis (BIA) is a complementary tool that assesses both intra- and extracellular fluid compartments. This study aims to correlate daily fluid balance with changes in muscle thickness and subcutaneous tissue measured by ultrasound, and to determine if BIA can accurately reflect fluid status and potentially identify edema in these patients.\n\nFurthermore, at ICU discharge, patients' muscle strength will be assessed using both the MRC-sum score (0-60) and handgrip strength (using a Jamar dynamometer), to investigate whether the presence of edema at discharge correlates with muscle strength deficits. Data collection will occur daily, tracking fluid balance, clinical parameters, and body weight, alongside ultrasound and BIA measurements in a standardized position. The study will help clarify the interactions between fluid management, muscle mass changes, and clinical outcomes in critically ill patients, providing valuable insight into early rehabilitation strategies.",[173,31,174,175,176,177],"Weakness Acquired in the ICU","Edema","Fluid Overload","Critical Illness","Intensive Care Unit (ICU) Patients",[179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206],"Muscle thickness","Subcutaneous tissue","Ultrasound","Bioelectrical impedance analysis","BIA","Fluid balance","ICU (intensive care unit)","Muscle strength","MRC-sum score","Grip strength","Edema assessment","Critical care","Skeletal muscle","Hydration status","Muscle echogenicity","ICU-acquired weakness","Fluid compartments","Extracellular water","Intracellular water","Body composition","Bedside ultrasound","Fluid management","Early mobilization","Volume overload","Tissue edema","Body water compartments","Length of ICU stay","Muscle quality","2024-11-17",{"date":209,"type":56},"2024-11-20",{"date":211,"type":56},"2024-10-21",{"date":213,"type":21},"2024-11-15",{"name":215,"class":63},"Dr F Duprez",2]